Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Protein homeostasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Protein homeostasis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-003283-31 Sponsor Protocol Number: NL67170.068.18 Start Date*: 2019-03-13
    Sponsor Name:School of Nutrition and Translational research in Metabolism (NUTRIM), Maastricht University
    Full Title: MaasFlex: A Double-Blind, Randomized, Phase IV, Mechanistic, Placebo-Controlled, Cross-Over, Single-Center Study to Evaluate the Effects of 2 Weeks Dapagliflozin Treatment on Nocturnal Substrate Ox...
    Medical condition: Study to investigate the effect of dapagliflozin treatment on nocturnal substrate oxidation in overweight and obese subjects with a disrupted glucose homeostasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001696-36 Sponsor Protocol Number: IL2REG Start Date*: 2019-10-09
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Study of efficacy of low-dose recombinant human interleukin-2 in immunological changes associated with depression (IL2REG)
    Medical condition: Depressive episode in course of mood disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10012402 Depressive episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002269-21 Sponsor Protocol Number: 01.00240 Start Date*: 2013-12-06
    Sponsor Name:Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto
    Full Title: Metformin in diastolic dysfunction of metabolic syndrome
    Medical condition: Diastolic dysfunction in non-diabetic patients with metabolic syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002634-20 Sponsor Protocol Number: NBF_HK_01_2018 Start Date*: 2018-10-23
    Sponsor Name:Anaesthesia Department, Hvidovre Hospital, Capital Region of Denmark
    Full Title: Highdose steroid for total knee arthroplasty - A randomized doubleblindet controlled trial.
    Medical condition: Perioperative management of total knee-arthroplasty because of knee-osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10023469 Knee arthroplasty PT
    20.1 100000004863 10054711 Postoperative pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-005644-26 Sponsor Protocol Number: 1.2012 Start Date*: 2014-12-23
    Sponsor Name:Atrium Medical Centre
    Full Title: Administration of intranvenous ferric carboxymaltose to children with IBD
    Medical condition: Anemia in children with Inflammatory Bowel Disease (IBD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000440-10 Sponsor Protocol Number: CADPT02A12001 Start Date*: 2020-02-21
    Sponsor Name:Novartis Pharma AG
    Full Title: NASH EXploratory Single and COmbination Treatment (NEXSCOT): An open label, multicenter, platform study to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and com...
    Medical condition: non-alcoholic fatty liver disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002470-86 Sponsor Protocol Number: 20190218 Start Date*: 2023-05-08
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without...
    Medical condition: Overweight and Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001998-25 Sponsor Protocol Number: BLO K025 Start Date*: 2006-09-29
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Double-blind, randomised trial to investigate the antihypertensive and metabolic effects of candesartan in insulin-resistant obese patients with a hypertension not adequately controlled by previous...
    Medical condition: Insulin-resistant obese patients with a hypertension not adequately controlled by previous beta-blocker or calcium channel blocker
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015488 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004527-32 Sponsor Protocol Number: SITADS Start Date*: 2016-11-22
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Kings College Hospital NHS Foundation Trust
    Full Title: Pilot randomised controlled trial of SITAgliptin for Depressive Symptoms in type 2 diabetes
    Medical condition: Depression in type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003183-75 Sponsor Protocol Number: 752/11 Start Date*: 2012-01-23
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: the role of vitamin D supplementation in the prevention of cardiovascular risk factors
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003901-23 Sponsor Protocol Number: K-001-201 Start Date*: 2022-05-11
    Sponsor Name:Kowa Research Institute, Inc
    Full Title: A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic N...
    Medical condition: Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004871 10086370 NASH with fibrosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022215-19 Sponsor Protocol Number: GHIGF1/2011 Start Date*: 2011-07-21
    Sponsor Name:Greater Glasgow & Clyde NHS
    Full Title: A Pharmacokinetic Study Of The Combined Use Of Recombinant Human GH And IGF-1 In Children With Inflammatory Bowel (Crohn’s) Disease
    Medical condition: Impaired growth in Paediatric Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10011398 Crohn's LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001625-16 Sponsor Protocol Number: PBI-4050-ATX-9-05 Start Date*: 2015-10-29
    Sponsor Name:ProMetic BioSciences Inc.
    Full Title: A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of its Effects on the Inflammatory, Fibrosis,Diabetes and Obesity Biomarkers in Subjects with Alström...
    Medical condition: Alström Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10068814 Alstrom syndrome LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000685-15 Sponsor Protocol Number: AXA1125-101 Start Date*: 2021-10-18
    Sponsor Name:Axcella Health, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of AXA1125 in Subjects With Non Cirrhotic, Non Alcoholic Steatohepatitis and Fi...
    Medical condition: Noncirrhotic, Nonalcoholic Steatohepatitis and Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000322-19 Sponsor Protocol Number: UX007-CL202 Start Date*: 2016-06-06
    Sponsor Name:Ultragenyx Pharmaceutial Inc.
    Full Title: An Open-label Long-Term Safety and Efficacy Extension Study in Subjects with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Previously Enrolled in UX007 or Triheptanoin Studies
    Medical condition: Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-001254-22 Sponsor Protocol Number: SARPAC Start Date*: 2020-03-24
    Sponsor Name:University Hospital Ghent
    Full Title: A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients wit...
    Medical condition: Acute hypoxic respiratory failure of COVID-19 patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10074615 Hypoxic respiratory failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005142-21 Sponsor Protocol Number: MLN1202-2005 Start Date*: 2015-05-20
    Sponsor Name:Takeda Development Centre Europe Limited
    Full Title: A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy Su...
    Medical condition: Diabetic Nephropathy: Adults (age 18 - 90 years inclusive) with type 2 diabetes, an eGFR of 25-59 mL/min/1.73 m2, and with macroalbuminuria (>300 mg/g) will be randomized.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-003840-22 Sponsor Protocol Number: D6160C00048 Start Date*: 2005-06-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Double-blind, Multi-centre, Active-Controlled (15, 30, and 45mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar (0.5 and 1 mg) in Patients wit...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    7 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016051-22 Sponsor Protocol Number: CL004_140 Start Date*: 2010-02-09
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus in subjects with insufficient glycemic control on a stable dose of metformin
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-003177-58 Sponsor Protocol Number: SPIOMET4HEALTH Start Date*: 2022-05-12
    Sponsor Name:Fundació Sant Joan de Déu (FSJD)
    Full Title: A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIO...
    Medical condition: Polycystic Ovary Syndrome (PCOS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: AT (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 06 10:31:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA